Pfizer Recruits Chief Development Officer William Pao From Roche R&D Team
Executive Summary
William Pao will oversee Pfizer's global product development organization, while Roche appointed Hans Clevers to take over from Pao as head of Roche’s pRED.
You may also be interested in...
William Pao On Pfizer’s ‘Aspirational’ Drug Development Goal, Seagen And More
Chief development officer William Pao oversees Pfizer’s clinical pipeline. He joined the company from Roche following a career in academia, and after his first year at Pfizer talked to Scrip about the transition to late-stage drug development.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: will 2022 herald more big M&A deals?; Novartis’s four R&D philosophies; new clinical holds at Gilead; Pfizer recruits new chief development officer from Roche; and Scrip asks what this year will bring in the markets, competition and business strategy areas.
Roche R&D Spending Surge Reflects In-House Innovation, M&A Prices
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.